Key result
Men achieve ~48% lower 6-month LDL-C levels than women on PCSK9 inhibitors.
Why the study?
Do men and women have different LDL-C and non-HDL-C responses to maximum tolerated doses of lipid-lowering agents and PCSK9 inhibitors?
Cohort (n=116)
No
Do men and women have different LDL-C and non-HDL-C responses to maximum tolerated doses of lipid-lowering agents and PCSK9 inhibitors?
Answers are grounded in this paper and cite their sources.
Men achieved significantly greater reductions in LDL-C and non-HDL-C than women when treated with maximum tolerated lipid-lowering agents and PCSK9 inhibitors, highlighting potential sex disparities in treatment response.
Background: Sex differences influence the response of low-density lipoprotein cholesterol (LDL-C) and nonhigh-density lipoprotein cholesterol (non-HDL-C) to lipid-lowering agents (LLAs). However, the effect of sex on newer medications such as proprotein convertase subtilisin/kexin-9 inhibitors (PCSK9Is) remains unclear, complicating sex-specific therapies for LDL-C and non-HDL-C targets. Objective: This study aimed to evaluate the clinical characteristics of Kuwaiti patients on LLAs and their LDL-C and non-HDL-C response to maximum tolerated doses of LLAs and PCSK9Is over 6 months, stratified by sex. Methods: Data were collected from patients at the Sabah Al-Ahmad Cardiac Center’s outpatient clinic from January 2021 to December 2023. Adults (≥18 years) on LLAs for over 3 months who provided consent were included in the study. Patients on the maximum tolerated doses of LLAs and those on PCSK9Is were stratified into males and females, and their total cholesterol, non-HDL-C, and LDL-C levels were assessed at baseline and at the 6-month follow-up. Results: Of 116 patients (48.3% male; mean age 50.5 ± 12.8 years), LDL-C and non-HDL-C levels were similar between sexes at baseline. After 6 months, LLAs showed a median LDL-C reduction of 26% ( P < 0.001). Men achieved better LDL-C levels (1.5 vs. 2.6 mmol/L, P < 0.001) and reached more treatment targets than women. PCSK9Is (alirocumab and evolocumab) significantly reduced LDL-C and non-HDL-C, with stronger responses in men (LDL-C: 1.3 vs. 2.5 mmol/L, P < 0.001; non-HDL-C: 2.2 vs. 3.4 mmol/L, P < 0.001). Conclusion: LLAs and PCSK9Is effectively lower LDL-C and non-HDL-C, but men show better outcomes, suggesting the need for sex-specific treatment strategies.
No takes yet. Share an insight, caveat, or question.
Shehab et al. (2025) conducted a cohort in Hyperlipidemia (n=116). Male sex (in patients on LLAs and PCSK9Is) vs. Female sex was evaluated on LDL-C levels at 6 months on PCSK9Is (mmol/L) (p=<0.001). Among patients on PCSK9 inhibitors, men achieved lower LDL-C levels at 6 months compared to women.
Synapse has enriched 10 related papers. Consider them for comparative context: